References
[1] W.K. Seto, Y.R. Lo, J.M. Pawlotsky, M.F. Yuen, Chronic hepatitis
B virus infection, Lancet 392(10161) (2018) 2313-2324.
[2] T.J. Liang, Hepatitis B: the virus and disease, Hepatology 49(5
Suppl) (2009) S13-21.
[3] C. Seeger, W.S. Mason, Molecular biology of hepatitis B virus
infection, Virology 479-480 (2015) 672-86.
[4] M. Nassal, HBV cccDNA: viral persistence reservoir and key
obstacle for a cure of chronic hepatitis B, Gut 64(12) (2015) 1972-84.
[5] M.G. Martinez, A. Boyd, E. Combe, B. Testoni, F. Zoulim,
Covalently closed circular DNA: The ultimate therapeutic target for
curing HBV infections, J Hepatol 75(3) (2021) 706-717.
[6] G.C. Fanning, F. Zoulim, J. Hou, A. Bertoletti, Therapeutic
strategies for hepatitis B virus infection: towards a cure, Nat Rev Drug
Discov 18(11) (2019) 827-844.
[7] Z. Shen, H. Yang, S. Yang, W. Wang, X. Cui, X. Zhou, W. Liu, S.
Pan, Y. Liu, J. Zhang, J. Zhang, Y. Xie, J. Liu, Hepatitis B virus
persistence in mice reveals IL-21 and IL-33 as regulators of viral
clearance, Nat Commun 8(1) (2017) 2119.
[8] Z. Shen, J. Liu, J. Wu, Y. Zhu, G. Li, J. Wang, M. Luo, Q. Deng,
J. Zhang, Y. Xie, IL-21-based therapies induce clearance of hepatitis B
virus persistence in mouse models, Theranostics 9(13) (2019) 3798-3811.
[9] G.P. Gao, M.R. Alvira, L. Wang, R. Calcedo, J. Johnston, J.M.
Wilson, Novel adeno-associated viruses from rhesus monkeys as vectors
for human gene therapy, Proc Natl Acad Sci U S A 99(18) (2002) 11854-9.
[10] D. Wang, P.W.L. Tai, G. Gao, Adeno-associated virus vector as a
platform for gene therapy delivery, Nat Rev Drug Discov 18(5) (2019)
358-378.
[11] M.M. Billingsley, N. Singh, P. Ravikumar, R. Zhang, C.H. June,
M.J. Mitchell, Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for
Human CAR T Cell Engineering, Nano Lett 20(3) (2020) 1578-1589.
[12] N.N. Zhang, X.F. Li, Y.Q. Deng, H. Zhao, Y.J. Huang, G. Yang,
W.J. Huang, P. Gao, C. Zhou, R.R. Zhang, Y. Guo, S.H. Sun, H. Fan, S.L.
Zu, Q. Chen, Q. He, T.S. Cao, X.Y. Huang, H.Y. Qiu, J.H. Nie, Y. Jiang,
H.Y. Yan, Q. Ye, X. Zhong, X.L. Xue, Z.Y. Zha, D. Zhou, X. Yang, Y.C.
Wang, B. Ying, C.F. Qin, A Thermostable mRNA Vaccine against COVID-19,
Cell 182(5) (2020) 1271-1283.e16.
[13] S. Ramachandran, S.R. Satapathy, T. Dutta, Delivery Strategies
for mRNA Vaccines, Pharmaceut Med 36(1) (2022) 11-20.
[14] G. Li, Y. Zhu, D. Shao, H. Chang, X. Zhang, D. Zhou, Y. Gao, K.
Lan, Q. Deng, Recombinant covalently closed circular DNA of hepatitis B
virus induces long-term viral persistence with chronic hepatitis in a
mouse model, Hepatology 67(1) (2018) 56-70.
[15] I.V. Zhigaltsev, N. Belliveau, I. Hafez, A.K. Leung, J. Huft,
C. Hansen, P.R. Cullis, Bottom-up design and synthesis of limit size
lipid nanoparticle systems with aqueous and triglyceride cores using
millisecond microfluidic mixing, Langmuir 28(7) (2012) 3633-40.
[16] R. Hong, W. Bai, J. Zhai, W. Liu, X. Li, J. Zhang, X. Cui, X.
Zhao, X. Ye, Q. Deng, P. Tiollais, Y. Wen, J. Liu, Y. Xie, Novel
recombinant hepatitis B virus vectors efficiently deliver protein and
RNA encoding genes into primary hepatocytes, J Virol 87(12) (2013)
6615-24.
[17] J. Köck, M. Nassal, S. MacNelly, T.F. Baumert, H.E. Blum, F.
von Weizsäcker, Efficient infection of primary tupaia hepatocytes with
purified human and woolly monkey hepatitis B virus, J Virol 75(11)
(2001) 5084-9.
[18] Z. Shen, J. Wu, Z. Gao, S. Zhang, J. Chen, J. He, Y. Guo, Q.
Deng, Y. Xie, J. Liu, J. Zhang, High mobility group AT-hook 1 (HMGA1) is
an important positive regulator of hepatitis B virus (HBV) that is
reciprocally upregulated by HBV X protein, Nucleic Acids Res 50(4)
(2022) 2157-2171.
[19] H. Schulze-Bergkamen, A. Untergasser, A. Dax, H. Vogel, P.
Büchler, E. Klar, T. Lehnert, H. Friess, M.W. Büchler, M. Kirschfink, W.
Stremmel, P.H. Krammer, M. Müller, U. Protzer, Primary human
hepatocytes–a valuable tool for investigation of apoptosis and
hepatitis B virus infection, J Hepatol 38(6) (2003) 736-44.
[20] L.M. Kattenhorn, C.H. Tipper, L. Stoica, D.S. Geraghty, T.L.
Wright, K.R. Clark, S.C. Wadsworth, Adeno-Associated Virus Gene Therapy
for Liver Disease, Hum Gene Ther 27(12) (2016) 947-961.
[21] P.R. Cullis, M.J. Hope, Lipid Nanoparticle Systems for Enabling
Gene Therapies, Mol Ther 25(7) (2017) 1467-1475.
[22] L.G. Guidotti, B. Matzke, H. Schaller, F.V. Chisari, High-level
hepatitis B virus replication in transgenic mice, J Virol 69(10) (1995)
6158-69.
[23] A.K. Raney, C.M. Eggers, E.F. Kline, L.G. Guidotti, M.
Pontoglio, M. Yaniv, A. McLachlan, Nuclear covalently closed circular
viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null
hepatitis B virus transgenic mice, J Virol 75(6) (2001) 2900-11.
[24] J.A. Kulkarni, D. Witzigmann, S. Chen, P.R. Cullis, R. van der
Meel, Lipid Nanoparticle Technology for Clinical Translation of siRNA
Therapeutics, Acc Chem Res 52(9) (2019) 2435-2444.
[25] Y. Li, L. Tang, J. Hou, Role of interleukin-21 in HBV
infection: friend or foe?, Cell Mol Immunol 12(3) (2015) 303-8.
[26] J. Publicover, A. Goodsell, S. Nishimura, S. Vilarinho, Z.E.
Wang, L. Avanesyan, R. Spolski, W.J. Leonard, S. Cooper, J.L. Baron,
IL-21 is pivotal in determining age-dependent effectiveness of immune
responses in a mouse model of human hepatitis B, J Clin Invest 121(3)
(2011) 1154-62.
[27] G. Ronzitti, D.A. Gross, F. Mingozzi, Human Immune Responses to
Adeno-Associated Virus (AAV) Vectors, Front Immunol 11 (2020) 670.
[28] D. Yang, L. Liu, D. Zhu, H. Peng, L. Su, Y.X. Fu, L. Zhang, A
mouse model for HBV immunotolerance and immunotherapy, Cell Mol Immunol
11(1) (2014) 71-8.